AKR1C3 activates the ERK signaling pathway to promote epithelial-mesenchymal transition and metastasis (1), conferring PCa cells with enzalutamide resistance (2), and is one of the factors contributing to cross-resistance of second-generation antiandrogen drugs (3). The gene discussed is AKR1C3; the disease is posterior cortical atrophy.